Benzinga | Jun 16, 2021 09:24AM EDT

Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

* Aprea Therapeutics Inc (NASDAQ:APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate.

* The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML.

* In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37%.

* The composite rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%.

* Eleven patients remain on study treatment and continue to be followed for safety and efficacy as of the data cut.

* The Company plans to discuss the dataset with the FDA in the second half of 2021.

* Data from the trial will be presented at a future scientific or medical conference.

* Price Action: APRE shares are up 49.7% at $7.26 during the premarket session on the last check Wednesday.